Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [9503]

Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous...

Dr Sheela Rao - The Royal Marsden, London, UK

Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal ( Dr Sheela Rao - The Royal Marsden, London, UK )

TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab...

Prof Peter Schmid - Barts Cancer Institute, London, UK

TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS compared to neoadjuvant chemo alone ( Prof Peter Schmid - Barts Cancer Institute, London, UK )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

Enzalutamide treatment boosted by Radium-223 in mCRPC

Prof Silke Gillessen - Oncology Institute of Southern Switzerland, Bellinzona...

Enzalutamide treatment boosted by Radium-223 in mCRPC ( Prof Silke Gillessen - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate...

Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer ( Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates...

Prof Nicolas Girard - Institut Curie, Paris, France

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Patient reported outcomes for telisotuzumab vedotin in c-Met protein...

Prof Nicolas Girard - Institut Curie, Paris, France

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Nivolumab plus ipilimumab improves efficacy versus standard of care in non...

Prof Lothar Bergmann - University Hospital Frankurt, Frankfurt am Main, Germany

Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell carcinomas ( Prof Lothar Bergmann - University Hospital Frankurt, Frankfurt am Main, Germany )

More from ecancer